Apollomics Inc.
APLMNext catalyst
APL-101
Metastatic Non Small Cell Lung Cancer
Get an email about APLM's next catalysts
Track Apollomics (APLM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
APL-101 Phase 2 Est. Readout
Estimated primary completion for APL-101 trial (NCT04743505) in Metastatic Non Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL-101 Oral Capsules | Phase 2 | Solid Tumors | - | - |
APL-101 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
Frequently asked questions
What is in Apollomics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Apollomics Inc.'s (APLM) pipeline across Phase 2. Its lead program is APL-101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apollomics Inc.'s next FDA catalyst?→
Apollomics Inc.'s (APLM) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APLM biotech catalysts?→
Add APLM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apollomics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.